Overview

A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

Status:
Recruiting

Trial end date:
2022-05-20

Target enrollment:

Participant gender:

Summary

This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it. After treatment, each participant will be followed up for up to 12 weeks. Participants will visit their study clinic up to 18 times during the study.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Collaborator:

Takeda Development Center Americas, Inc.

Treatments:

Ganciclovir
Maribavir
Valganciclovir